1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

Authors :: J.S. Weber
Mario Mandalà
L. de la Cruz Merino
Helen Gogas
V. Chiarion Sileni
J.-J. Grob
Marcus O. Butler
A.M. Arance Fernandez
P.A. Ascierto
Charles Lance Cowey
S. Dalle
M. Del Vecchio
V. de Pril
Michele Maio
Michael Schenker
Mark R. Middleton
Ivan Marquez-Rodas
Maurice Lobo
J.M.G. Larkin
Source :: Annals of Oncology. 31:S731-S732
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Melanoma
medicine.medical_treatment
Checkmate
Ipilimumab
Hematology
medicine.disease
Internal medicine
medicine
Overall survival
Stage (cooking)
Nivolumab
business
Adjuvant
medicine.drug

Full Text Access

Tools